Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting

64

BOSTON–(BUSINESS WIRE)–Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that two posters highlighting clinical data for COPIKTRA™ (duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were presented at the European Hematology Association (EHA) 2019 …

 

 

 

 

 

http://www.businesswire.com/news/home/20190617005144/en/Verastem-Oncology-Presents-COPIKTRA%E2%84%A2-Duvelisib-Data-European/